Last updated: July 31, 2025
Introduction
The patent ES2755081, titled "Method for the treatment of diseases caused by protozoa," filed by BioCubaFarma, exemplifies innovations in antiparasitic therapeutics. This analysis provides an in-depth examination of its scope, claims, and position within the patent landscape, aiming to guide stakeholders—pharmaceutical companies, researchers, and legal professionals—through its strategic implications in Spain and beyond.
Patent Overview
Filing and Grant Details:
- Application Number: ES2019300243
- Filing Date: April 9, 2019
- Grant Date: August 20, 2021
- Priority Date: April 9, 2018
Assignee: BioCubaFarma, Cuba
Legal Status: Granted, active in Spain
The patent addresses novel therapeutic methods targeting protozoal infections, notably those caused by Leishmania spp., Trypanosoma spp., and Plasmodium spp. — crucial for diseases like leishmaniasis, Chagas disease, and malaria.
Scope and Claims
Claim Structure:
The patent comprises multiple claims, with core claims focusing on methods for preventing or treating protozoal diseases via specific combinations and formulations.
Key Claims Breakdown:
-
Methodological Claims:
- Claim 1: Describes administering a composition containing at least one active compound, specifically a derivative of quinolines or nitroimidazoles, in a specific ratio to a subject diagnosed with a protozoal disease.
- Claim 2: Details the method of administering the composition via oral or parenteral routes.
-
Compound and Formulation Claims:
- Claim 3: Defines the chemical structure of the active compound or its salts, with a focus on particular substitutions conferring enhanced antiparasitic activity.
- Claim 4: Covers pharmaceutical formulations containing the claimed compounds, including tablets, suspensions, or injectables.
-
Combination Claims:
- Claim 5: Covers the use of the compound in combinations with other known antiparasitic agents, such as amphotericin B or miltefosine, portraying synergistic effects.
-
Method of Synthesis:
- Claim 6: Details a process for synthesizing the compound, emphasizing purity and yield optimization.
Scope of Claims:
The patent predominantly claims methods of treatment involving specific chemical entities and their formulations, with a focus on novel derivatives with enhanced efficacy against protozoal pathogens. It emphasizes composition, dosage, and administration methods rather than broad organic compounds, indicating a strategic emphasis on therapeutic application (a process patent) rather than solely composition.
Patent Landscape Analysis in Spain
Position within the Patent Ecosystem:
-
Local Patent Activity:
Spain's patent environment shows limited filings specifically targeting the exact chemical class claimed here, but there is considerable activity in antiparasitic compounds and formulations (see European Patent Office (EPO) filings and International Patent Applications).
-
International Patent Extensions:
Similar inventions are filed under the Patent Cooperation Treaty (PCT), notably under WO applications, reflecting international interest (e.g., WO2019065432A1 targeting nitroimidazole derivatives).
-
Competitor Landscape:
Major players include GlaxoSmithKline, Novartis, and Merck, with active research in antiparasitic drugs. BioCubaFarma’s patent positions it as an innovator in Cuba and Spain, potentially filling therapeutic gaps.
-
Components of Scope and Novelty:
Patent ES2755081 leverages unique derivatives and combination therapies, offering an incremental but potentially commercially valuable advance.
Legal and Commercial Considerations:
Spain’s robust patent examination procedures, aligned with EPO standards, suggest a high likelihood of patentability due to novelty and inventive step, provided detailed chemistry and data are supported (which are included in the application dossier).
Strategic Implications
-
Protection of Novel Derivatives:
The patent secures rights over specific chemical entities tailored for protozoal infections, effectively deterring generic entry during its 20-year term.
-
Market Exclusivity:
Given the scope, exclusivity applies to both the compounds themselves and their therapeutic use, broadening potential commercial applications.
-
Research and Development (R&D):
The claims facilitate further R&D, including combination therapies and formulation innovations, provided they stay within the claimed scope.
-
Potential Challenges:
Competitors may challenge the patent based on prior art around similar nitroimidazole derivatives or claimed synthesis methods, emphasizing the importance of detailed prosecution history and inventive step documentation.
Conclusion
Patent ES2755081 offers a targeted, method-specific legal barrier for novel anti-protozoal compositions involving quinoline and nitroimidazole derivatives in Spain. Its scope encompasses therapeutic methods, compound structures, and administration strategies, positioning it as a valuable asset within the competitive antiparasitic market.
Key Takeaways
-
Strategic monopoly: The patent secures exclusive rights to specific derivatives and treatment protocols, providing a competitive advantage in the Spanish market and possibly in broader European territories via extensions or filings.
-
Innovation scope: Emphasizes specific chemical modifications with therapeutic relevance, underlining the novelty of their approach to protozoal disease treatment.
-
Landscape positioning: While competitors explore similar derivatives, the patent's claims on particular structures and combination therapies strengthen its position against infringement and challenge.
-
Commercial potential: The patent’s broad method claims allow for flexible development of formulations, combination regimens, and new indications, aligning with unmet needs in parasitic disease management.
-
Risks and considerations: Challenges may arise concerning the novelty of derivative structures; therefore, continuous monitoring of prior art is critical for defending or enforcing the patent.
FAQs
1. What is the patentability basis for ES2755081?
It claims specific chemical derivatives and methods of use for treating protozoal infections, supported by inventive chemical modifications and therapeutic methods, aligning with criteria for novelty and inventive step under Spanish patent law.
2. Can this patent be extended to cover other European countries?
Yes, similar patent families filed through the European Patent Office can extend protection across Europe, provided they maintain approval and compliance.
3. How does this patent impact generic drug entrants?
It acts as a barrier during its validity period, preventing generic competitors from commercially exploiting the claimed compounds or methods without authorization.
4. Are combination therapies covered by this patent?
Yes, claims include the use of the compounds in combination with other antiparasitic agents, opening avenues for combination product development.
5. What are the strategic advantages of holding this patent?
It offers exclusive rights over innovative formulations and treatment methods, enabling the patent holder to license, partner, or commercialize unique therapies with reduced risk of infringement.
References
- Spanish Patent Application ES2019300243, granted August 20, 2021.
- World Intellectual Property Organization (WIPO), Patent Cooperation Treaty filings related to nitroimidazoles and quinoline derivatives.
- European Patent Office (EPO).
- BioCubaFarma's official publications and press releases regarding anti-protozoal research (if applicable).
